People with schizophrenia tend to hallucinate and “hear voices” that aren’t possible for others to observe. The serious ...

Many researchers believe that schizophrenia can affect a person's ability to smell and how they perceive smells. However, the ...

Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...

Popular depictions of schizophrenia often focus on visual hallucinations, but auditory hallucinations are far more common. At ...

Doctors sometimes use lithium to treat schizophrenia. However, it is not a primary treatment method and evidence of its ...

For the first time in nearly 30 years, the U.S. Food and Drug Administration has approved a new drug treating schizophrenia, ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

Researchers identified that impaired corollary discharge (CD) and noisy efference copy (EC) in schizophrenia disrupt ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...